LACERO
9.6.2020 09:02:08 CEST | Business Wire | Press release
Lacero, a next generation governance technology provider for digital assets, today announced the launch of FlowOS, offering advanced transaction control and permissioning. FlowOS is now live with major cryptocurrency liquidity provider B2C2.
FlowOS enhances existing wallet and custody solutions, giving users direct, independent control of their policies, procedures and rules. A radically different solution, it is the first platform to leverage blockchain technology to create a decentralised, immutable security architecture by constructing policy from independently certified smart contracts.
Introducing real-time governance, traceability and auditability, it makes it impossible to substitute, manipulate or circumvent approved policies and procedures, and enables reliable exception-based processing with a combination of programmable rules, automated workflow procedures and human approvals.
B2C2 has selected Lacero for its best-in-class technology for governance, controls and procedures. B2C2’s integration of FlowOS, in combination with its existing integration of Fireblocks’ cutting-edge payments technology, will further enhance the firm’s settlement capabilities – the largest by some margin in the OTC markets – for the benefit of its clients.
This combination of technology platforms further demonstrates B2C2’s bank-grade security and compliance standards which, twinned with its award-winning technology and the tightest and most consistent pricing, has made it the OTC liquidity provider of choice to the largest institutional names in the industry.
B2C2’s settlement platform, enhanced by the decentralised, auditable solutions offered by Lacero and Fireblocks, is setting a market standard for straight-through-processing that is applicable to both cryptocurrency and traditional financial markets.
Rashid Hoosenally, CEO of Lacero, said: “We’re excited to be partnering with a proven industry leader who shares our vision for institutional-grade governance and controls. B2C2 strive to continuously optimise processes and tailor workflows, so we’re delighted that FlowOS has been selected to provide them with a secure, flexible enforcement platform that can support them as they grow the scale, speed and breadth of their offering.”
Max Boonen, Founder and Group CEO of B2C2, said: “B2C2’s mission to bring best practices to the trading of digital assets spans both execution and post-trade. The ability to streamline and automate both trading and settlement is the next frontier in our industry. Enhancing the B2C2 platform with Lacero’s innovative technology will allow us to better serve our clients and further scale our business as the go-to counterparty.”
Simon Heinrich, CIO and Group Head of Technology at B2C2, said: “Operational excellence and client service are at the heart of what we do at B2C2 as we are relied upon to provide institutional-grade liquidity 24/7. Given the trustless environment and irreversibility of transactions in the continuously traded and settled crypto markets, FlowOS represents a critical component of our offering as it enables controlled autonomy of our processes in a demonstrably secure way.”
-Ends-
About Lacero
Lacero develops innovative technology for governing and safeguarding digital assets and data. Its platform is underpinned by blockchain, certified smart contracts and highly secure cryptographic methods. Based in the UK, Lacero was awarded Best RegTech Policy Platform 2020
in Wealth and Finance International’s FinTech Awards. For more information on Lacero’s FlowOS platform, please visit https://www.lacero.io
About B2C2
Founded in 2015, B2C2 is the leading cryptocurrency liquidity provider. Awarded Cryptocurrency Innovation of the Year
in 2020 by FStech and Best Institutional Crypto Liquidity Provider
in 2019 by the readers of Profit & Loss, B2C2 bridges the gap between traditional financial and cryptocurrency markets. The company is trusted by brokerages, exchanges, banks and fund managers to provide 24/7 liquidity. Headquartered in the UK, with offices in London, Jersey City and Tokyo, the firm is privately held. For more information, please visit https://www.b2c2.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200609005015/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom